Inspyr Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 14, 2020 at 03:38 pm EDT
Share
Inspyr Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced operating loss was USD 115,000 compared to USD 150,000 a year ago. Net loss was USD 1.175 million compared to USD 838,000 a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 4.19 a year ago. For the half year, operating loss was USD 240,000 compared to USD 362,000 a year ago. Net loss was USD 1.901 million compared to USD 913,000 a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 4.65 a year ago.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
REBUS HOLDINGS, INC. 
